PEPTIC CUP RESULTS

We are pleased to announce the winner of the PEPTIC Cup: Sturgeon ICU!

Honorable mentions go to the Teams from the MAZ CVICU (2nd Place) and the Misericordia ICU (3rd Place).

On behalf of all PEPTIC investigators and study personnel, we would like to extend a special thanks to all teams from all 8 participating ICUs.

Thanks to your efforts, Alberta will contribute data on over 3300 patients to this worldwide study. This has been a major accomplishment and hopefully the seed for more opportunities for similarly designed pragmatic trials in the future.

We anticipate data on the results from PEPTIC (both international and Alberta) to be available in the new year and we will share with all sites as soon as feasible.

Publications

COMPACT Study was recently published in the Journal of the American Heart Institute

https://www.ahajournals.org/doi/pdf/10.1161/JAHA.118.009917

A total of 126 patients undergoing non-emergent cardiac surgery were enrolled from the Mazankowski Heart Institute from April 2014 to June 2017

Enrollment Updates:

STARRT-AKI: GS-ICU: 31
CV-ICU: 3
BALANCE: 40
ALFSG: 68
ROTEM: 1
PROSPECT: 23

Currently Enrolling

ALFSG - Acute Liver Failure Study Group: A Multi-Center Group to Study Liver Failure

PI: Dr. Dean Karvellas
Lead Study Coordinator: Nadia Baig
Study Sponsor: UT Southwestern Medical Center at Dallas, Texas
❖ Observational study involving blood collection for 7 consecutive days during ICU study

ROTEM: Potential Use of Rotational Thromboelastometry to Explore Hemostatic Abnormalities in Patients with Acute Liver Failure

PI: Dr. Dean Karvellas
Lead Study Coordinator: Nadia Baig
Study Sponsor: UT Southwestern Medical Center at Dallas, Texas
❖ Observational Study involving blood collection from ALFSG study participants to provide an assessment of overall hemostasis in whole blood.

BALANCE Trial: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): Randomized control trial

PI: Dr. Wendy Sligl
Lead Study Coordinator: Lorena McCoshen
Study Sponsor: Sunnybrook Research Institute – Toronto
❖ Interventional Randomized Concealed allocation Trial of shorter duration (7 days) versus longer duration (14 days) antibiotic treatment for patients with bloodstream infections.

PROSPECT Trial: Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial

PI: Wendy Sligl
Lead Study Coordinator: Lorena McCoshen
Study Sponsor: McMaster University
❖ Interventional Randomized Controlled Trial to determine, in mechanically ventilated critically ill patients, whether enteral L. rhamnosus GG prevents VAP and other infections

STARRT-AKI Trial: STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial

PI: Dr. Sean Bagshaw
Lead Study Coordinator: Nadia Baig
Study Sponsor: St. Michaels Hospital - Toronto
❖ Interventional Randomized Controlled Trial to determine whether, in critically ill patients with severe AKI, randomization to accelerated initiation of RRT, compared to a conservative strategy consistent with standard care, leads to:
   1. Improved survival (primary outcome) at 90 days; and
   2. Recovery of kidney function (principal secondary outcome), defined as independence from RRT at 90 days

Winter Closure

In accordance with the University of Alberta Winter Closure the Research Office will be closed from December 24th – January 1st

To find out more about any study or ways you can be involved contact Dr. Sean Bagshaw, Director of Research at 780-248-1256, Nadia Baig, Research Manager at 780-492-3817, or visit our website at www.ualberta.ca/critical-care/research